Welcome to our dedicated page for Tandem Diabetes Care news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes Care stock.
Tandem Diabetes Care, Inc. (symbol: TNDM) is a leading medical device company committed to enhancing the lives of individuals with diabetes through continuous innovation and a customer-first approach. Based in San Diego, California, Tandem focuses on the design, development, and commercialization of advanced insulin pump technologies.
The company's flagship products include the t:slim X2™ insulin pump, noted for its unique ability to receive remote feature updates via a personal computer, and the t:flex® insulin pump, which is tailored for patients with higher insulin requirements. These devices are designed to offer users greater flexibility, control, and ease of use, significantly improving diabetes management.
In addition to these main products, Tandem has introduced the Mobi pump, a smaller, more discreet device, and is actively working on developing a tubeless pump to further enhance user convenience and experience. The company's product portfolio generates substantial revenue from both the insulin pumps themselves and the accompanying disposable infusion sets, which need regular replacement every 2 to 3 days.
Approximately 75% of Tandem's total revenue comes from the U.S. market, with the remaining sales derived from other developed countries. The company's strong focus on innovation and user experience has cemented its position as a trusted name in diabetes care.
For the latest updates and relevant information about Tandem Diabetes Care, Inc., including recent achievements, ongoing projects, financial performance, and strategic partnerships, stay tuned to our news section.
Note: This description is for informational purposes only and is not intended for product support or medical advice. In case of a medical emergency, please dial 911. For immediate assistance with Tandem products, contact the 24-hour customer support team at 877-801-6901, pressing 1 twice.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to release its first quarter 2021 results after market close on May 5, 2021. A conference call will follow at 4:30 PM ET to discuss the financial and operational results. Shareholders and interested parties can access details via dial-in numbers or through a live webcast. Tandem Diabetes is known for its innovative insulin delivery solutions, particularly the t:slim X2™ insulin pump that features remote software updates and integrated continuous glucose monitoring.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced management will present a company update at two upcoming virtual investor conferences. The presentations are scheduled for the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 PM ET and the Oppenheimer’s 31st Annual Healthcare Conference on March 17, 2021, at 2:30 PM ET. The updates will be webcast live, with an archive available for 30 days on Tandem's Investor Center website. This showcases Tandem's commitment to transparency and engagement with investors.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has appointed Jordan Pinsker, MD, as Vice President and Medical Director, effective April 26, 2021. Dr. Pinsker, a renowned pediatric endocrinologist, previously led artificial pancreas research at Sansum Diabetes Research Institute, where he directed clinical trials for automated insulin delivery systems. His extensive experience in diabetes care and technology aligns with Tandem's mission to enhance insulin therapy management. The leadership addition aims to drive innovation in closed-loop insulin delivery and improve outcomes for individuals with diabetes.
Tandem Diabetes Care reported strong financial results for Q4 and FY 2020, with worldwide pump shipments increasing 67% to 32,685 and sales rising 55% to $168.1 million compared to Q4 2019. For the full year, sales reached $498.8 million, a 38% increase, while the gross profit improved 34% to $260.5 million. The company anticipates 20-23% sales growth for 2021, estimating revenue between $600 million and $615 million, with a gross margin of approximately 55%.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at various virtual investor conferences, highlighting its commitment to innovation in diabetes technology. Key events include the Citi 2021 Healthcare Services Conference on February 25, the SVB Leerink Global Healthcare Conference on February 26, the Raymond James 42nd Annual Institutional Investors Conference on March 1, and the Cowen 41st Annual Healthcare Conference on March 2. Live webcasts will be available, with recordings archived for 30 days on their Investor Center website.
For more information, visit investor.tandemdiabetes.com.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is set to announce its fourth quarter and full year 2020 results on February 24, 2021. The announcement will be followed by a conference call at 4:30 PM ET to discuss financial and operational outcomes. Investors can access the live webcast and find an archived version for 30 days after the event. Tandem is known for its innovative t:slim X2 insulin pump, which features remote software updates and integrated continuous glucose monitoring, emphasizing its commitment to diabetes care improvement.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced the appointment of Rajwant (Raj) Singh Sodhi as an independent board member effective January 1, 2021. He succeeds Edward Cahill, who has served since May 2009. Raj, president of the SaaS business at ResMed, brings over 25 years of digital strategy experience across healthcare, financial services, and telecom. Tandem's CEO, John Sheridan, highlighted Raj's expertise in software technologies as valuable for the company's growth and innovation in diabetes care.
Tandem Diabetes Care (TNDM) reported strong Q3 2020 results with a 31% increase in sales to $123.6 million, up from $94.7 million in Q3 2019. Worldwide pump shipments rose 23% to 22,021 units. Domestic sales surged 36% to $107.5 million, while international sales saw a modest 2% increase. Although operating margin improved to negative 1%, a net loss of $9.4 million was recorded, higher than the previous year’s $2.9 million loss. The company updated its 2020 sales guidance to $465-$475 million, expecting 28%-31% annual growth.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) has announced upcoming presentations at three significant virtual investor conferences. The first will take place at the 29th Annual Credit Suisse Healthcare Conference on November 9, 2020, at 2:00 p.m. ET. The second event is the Stifel 2020 Healthcare Conference on November 17, 2020, at 4:40 p.m. ET. Lastly, the Nasdaq 43rd Investor Conference will occur on December 4, 2020, at 12:30 p.m. ET. Webcasts of these presentations will be available live and archived for 30 days on the company’s Investor Center website.
Tandem Diabetes Care (NASDAQ: TNDM) will announce its third quarter 2020 results on November 5, 2020, after market close. A conference call and webcast will be held at 4:30 PM ET to discuss the financial and operational results. This session can be accessed through a toll-free number or via a webcast link. An archive of the event will be available for 30 days on the company’s Investor Center website. Tandem is known for its innovative insulin delivery systems, notably the t:slim X2 insulin pump.
FAQ
What is the current stock price of Tandem Diabetes Care (TNDM)?
What is the market cap of Tandem Diabetes Care (TNDM)?
What is Tandem Diabetes Care, Inc. known for?
Where is Tandem Diabetes Care, Inc. located?
What are the main products of Tandem Diabetes Care, Inc.?
How do the t:slim X2™ insulin pump updates work?
What percentage of Tandem Diabetes Care's revenue comes from the U.S.?
Does Tandem Diabetes Care offer customer support?
What recent products has Tandem Diabetes Care introduced?
What materials are required to replace in Tandem's insulin pumps?
What is the unique feature of the t:flex® insulin pump?
How does Tandem Diabetes Care innovate in diabetes care?
